Hubro Therapeutics AS acquires GM-CSF vaccine adjuvant from Targovax ASA in asset purchase agreement
· Hubro acquires the GM-CSF project from Targovax for a cash payment of NOK10m · Hubro will continue the development of GM-CSF as adjuvant for use with its pipeline of novel cancer vaccines Oslo, Norway, 10 November 2022 – Targovax ASA (OSE: TRVX) and Hubro Therapeutics AS (Hubro) today announce that they have entered into an asset purchase agreement whereby Hubro acquires Targovax’s GM-CSF (Granulocyte macrophage colony-stimulating factor) process development and production project. Under the agreement, Hubro will make a cash payment to Targovax of 10MNOK for the acquisition of